AbbVie Inc. $ABBV Position Increased by Xponance LLC

Xponance LLC raised its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 3.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 479,552 shares of the company’s stock after purchasing an additional 15,898 shares during the period. AbbVie comprises about 0.8% of Xponance LLC’s portfolio, making the stock its 15th largest holding. Xponance LLC’s holdings in AbbVie were worth $109,573,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in AbbVie by 0.3% during the third quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company’s stock valued at $41,155,601,000 after purchasing an additional 448,554 shares during the last quarter. Public Sector Pension Investment Board grew its position in shares of AbbVie by 17.0% during the third quarter. Public Sector Pension Investment Board now owns 1,044,690 shares of the company’s stock worth $241,888,000 after acquiring an additional 151,644 shares during the last quarter. Thornburg Investment Management Inc. grew its position in shares of AbbVie by 25.5% during the third quarter. Thornburg Investment Management Inc. now owns 401,760 shares of the company’s stock worth $93,024,000 after acquiring an additional 81,625 shares during the last quarter. Channing Capital Management LLC grew its position in shares of AbbVie by 10.5% during the third quarter. Channing Capital Management LLC now owns 55,647 shares of the company’s stock worth $12,885,000 after acquiring an additional 5,302 shares during the last quarter. Finally, Procyon Advisors LLC grew its position in shares of AbbVie by 19.9% during the fourth quarter. Procyon Advisors LLC now owns 32,752 shares of the company’s stock worth $7,484,000 after acquiring an additional 5,427 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Stock Up 0.0%

Shares of ABBV opened at $225.04 on Friday. The firm has a 50-day moving average price of $210.80 and a 200 day moving average price of $219.01. The firm has a market capitalization of $397.60 billion, a PE ratio of 110.86, a P/E/G ratio of 0.69 and a beta of 0.32. AbbVie Inc. has a 52-week low of $181.73 and a 52-week high of $244.81.

AbbVie (NYSE:ABBV) last announced its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The firm had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. During the same quarter in the prior year, the firm posted $2.46 EPS. AbbVie’s revenue was up 12.4% compared to the same quarter last year. On average, equities analysts expect that AbbVie Inc. will post 14.3 EPS for the current year.

Wall Street Analysts Forecast Growth

ABBV has been the subject of several recent research reports. Wall Street Zen lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Sunday, June 7th. Morgan Stanley upped their price target on shares of AbbVie from $270.00 to $278.00 and gave the stock an “overweight” rating in a research report on Thursday, April 30th. Cantor Fitzgerald restated an “overweight” rating and set a $240.00 price target on shares of AbbVie in a research report on Thursday, April 30th. Canaccord Genuity Group upped their price target on shares of AbbVie from $262.00 to $265.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Finally, DZ Bank upgraded shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 30th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and an average price target of $253.43.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie said new Phase 3 data for venetoclax in first-line chronic lymphocytic leukemia showed durable, long-term treatment outcomes, supporting confidence in the drug’s commercial runway and oncology pipeline. Article link
• Positive Sentiment: AbbVie’s Skyrizi and Rinvoq continue to drive top-line growth, with strong first-quarter performance and new indications helping lift 2026 sales expectations. Article link
• Positive Sentiment: One article highlighted that promising clinical updates could help AbbVie fund future dividend growth, reinforcing the stock’s appeal for income-focused investors. Article link
• Neutral Sentiment: AbbVie was also mentioned in market commentary and “final trades” segments, which can increase attention but do not by themselves change the company’s fundamentals. Article link
• Negative Sentiment: AbbVie received a Complete Response Letter for its fast-acting neurotoxin TrenibotE, with the FDA citing manufacturing issues; while no safety or efficacy concerns were raised, the setback delays a potentially important aesthetics product. Article link

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.